D
Adverum Biotechnologies, Inc. ADVM
$4.23 -$0.03-0.70% NASDAQ
Recommendation
Prev Close
$4.23
Volume
806
Avg Vol (90D)
467,887
Market Cap
$88.76M
Dividend & Yield
--
52-Week Range
$1.78 - $8.18
P/E (TTM)
--
EPS (TTM)
-$8.78
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Consensus Recommendation of "Hold" from Analysts
10/29/2025 - MarketBeat
Adverum Biotechnologies price target lowered by $6.50 at Mizuho
10/29/2025 - The Fly
What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?
10/29/2025 - Zacks Investment Research
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cabaletta Bio (CABA), Actinium Pharmaceuticals (ATNM) and Adverum Biotechnologies (ADVM)
10/28/2025 - TipRanks Financial Blog
Adverum Biotechnologies price target raised by $1 at RBC Capital, here's why
10/28/2025 - The Fly
Adverum Biotechnologies (NASDAQ:ADVM) Stock Rating Lowered by Chardan Capital
10/28/2025 - MarketBeat
HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
10/27/2025 - PR Newswire
Buy, Sell or Hold Lilly Stock? Key Tips Ahead of Q3 Earnings
10/27/2025 - Zacks Investment Research
ADVM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adverum Biotechnologies, Inc. Is Fair to Shareholders
10/27/2025 - Business Wire
Adverum Biotechnologies (ADVM) Expected to Announce Earnings on Monday
10/27/2025 - MarketBeat
Adverum Biotechnologies (NASDAQ:ADVM) Receives Sell (D-) Rating from Weiss Ratings
10/25/2025 - MarketBeat
Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM
10/25/2025 - Business Wire
Adverum Biotechnologies (NASDAQ:ADVM) Share Price Crosses Above 50-Day Moving Average - Here's What Happened
10/25/2025 - MarketBeat
Adverum Biotechnologies downgraded to Neutral from Buy at Chardan
10/25/2025 - TipRanks Financial Blog
Adverum Biotechnologies just downgraded at Chardan, here's why
10/25/2025 - The Fly
Adverum Biotechnologies (ADVM) was downgraded to a Hold Rating at Chardan Capital
10/25/2025 - TipRanks Financial Blog
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Adverum Biotechnologies, Inc. (NASDAQ: ADVM)
10/24/2025 - PR Newswire
M&A News: Eli Lilly's (LLY) $262M Acquisition of Adverum Bolsters Gene Therapy Push
10/24/2025 - TipRanks Financial Blog
Halper Sadeh LLC Encourages ADVM, MOFG, HSII Shareholders to Contact the Firm to Discuss Their Rights
10/24/2025 - Globe Newswire
Shareholder Alert: The Ademi Firm investigates whether Adverum Biotechnologies, Inc. ...
10/24/2025 - GuruFocus
Adverum Biotechnologies just downgraded at Truist, here's why
10/24/2025 - The Fly
Shareholder Alert: The Ademi Firm investigates whether Adverum Biotechnologies, Inc. is obtaining a Fair Price for its Public Shareholders
10/24/2025 - PR Newswire
ADVM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adverum Biotechnologies, Inc. is Fair to Shareholders
10/24/2025 - Globe Newswire
Eli Lilly (LLY) Announces Acquisition of Adverum Biotechnologies
10/24/2025 - GuruFocus
Eli Lilly (LLY) to Acquire Adverum Biotechnologies in Deal Worth Up to $12.47 Per Share
10/24/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
$1.00M
EBITDA (TTM)
-$186.60M
EBIT (TTM)
-$189.51M
Net Income (TTM)
-$183.87M
Balance Sheet
Total Assets (Q)
$96.18M
Total Debt (Q)
$92.22M
Total Liabilities (Q)
$116.40M
Book Value Per Share (Q)
-$0.9636
Cash Flow
Cash from Operations (TTM)
-$130.91M
Cash from Investing (TTM)
$45.65M
Cash from Financing (TTM)
$359.00K
Net Change in Cash (TTM)
-$84.90M
Filings
Filing Date
Tuesday, August 12, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 3 and 7 (est)
Price History
Loading...
Beta
0.86
7-Day Total Return
-5.37%
30-Day Total Return
43.39%
60-Day Total Return
67.86%
90-Day Total Return
66.54%
Year to Date Total Return
-11.88%
1-Year Total Return
-46.32%
2-Year Total Return
-51.38%
3-Year Total Return
-51.10%
5-Year Total Return
-96.12%
52-week Low
May 15, 2025 - $1.78
52-week High
Nov 11, 2024 - $8.18
Valuation
Market Cap
$88.76M - Micro Cap
Enterprise Value
$136.59M
Price/Sales (TTM)
89.05
Price/Book (Q)
-4.39
Dividends and Shares
Shares Outstanding
21.01
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
adverum.com
Phone Number
650 656 9323
Address
100 Cardinal Way
Redwood City, CA 94063
Country
United States
Year Founded
2006
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a... more
NASDAQ 10/29/2025 4:00PM Eastern Quotes delayed